Profile

ProteinQure has built the best computational platform for designing small exotic protein therapeutics. It combines molecular simulations and machine learning to do the structure-based design of drugs and uses novel peptides to help deliver payloads in a tissue-specific manner. Its platform has been validated (in-vivo and with unprecedented in-vitro characteristics) with three top 25 pharma companies in their experimental assays and is the only computational platform capable of designing peptides with the full complement of non-canonical amino acids so that its peptides are 100x better than natural peptide ligands. ProteinQure is not selling software; its partnership model involves upfront fees and milestones. The company is working on its first assets and has in-vivo efficacy for its first program in oncology. Its Series A in 2023 will support the build-out of the internal pipeline.


Event details

Date: June 5 - 8, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

33 in total